Health Insurance Expenditure Structure for Type 2 Diabetes Treatment in Vietnam by Hospital Classification, 2018-2022: A Descriptive Analysis of Claims Data From Hanoi and Ho Chi Minh City

Background Type 2 diabetes mellitus (T2DM) is a chronic disease that imposes a significant burden on healthcare systems and society. In Vietnam, the prevalence of T2DM is rapidly increasing; however, evidence on treatment expenditure derived from large administrative databases remains limited. This study was carried out provides an overview of total treatment expenditures for T2DM across hospital tiers between 2018 and 2022. Methods This cross-sectional descriptive study utilized retrospective health insurance (HI) data from 2018-2022. Data was collected and analyzed based on cost components (medications, diagnostic tests, hospital beds, etc.) across healthcare facilities classified by hospital level. Costs were converted to 2024 USD using the CCEMG-EPPI-Centre cost converter. Results Total expenditure increased from 227.17 million USD in 2018 to 425.53 million USD in 2022 with spending concentrated in Class I and Class II healthcare facilities, although their shares declined over time, while the proportions attributed to unclassified and special-class facilities increased. Drugs accounted for the largest share of expenditure (49.65%-78.95%), followed by laboratory tests (7.31%-19.89%) across all hospital classifications. Other components, including hospital beds, diagnostic imaging, procedures/surgeries, and medical supplies, contributed smaller proportions but increased over time in several facility groups. Conclusion The study indicates that medication costs constitute the largest share of treatment expenditure for type 2 diabetes mellitus at healthcare facilities, reflecting the long-term treatment requirements of this chronic disease. In addition, health expenditure remained concentrated in Class I and Class II healthcare facilities, although their shares declined over the study period, while the proportions attributed to unclassified and special-class facilities increased. These findings suggest the need to strengthen diabetes screening, treatment, and follow-up at lower-level healthcare facilities in order to reduce the burden on higher-level hospitals and improve the efficiency of healthcare resource allocation.